Abstract
Following on the recent publication of pharmacologically relevant effects, small molecule inhibitors of adipocyte fatty-acid binding protein 4 (FABP4) have attracted high interest. FABP4 is mainly expressed in macrophages and adipose tissue, where it regulates fatty acid storage and lipolysis, being also an important mediator of inflammation. In this regard, FABP4 recently demonstrated an interesting molecular target for the treatment of type 2 diabetes, other metabolic diseases and some type of cancers. In the past years, hundreds of effective FABP4 inhibitors have been synthesized. In this paper, a quantitative structure-activity relationship (QSAR) model has been produced, in order to predict the bioactivity of FABP4 inhibitors. The methodology has been combined with a scaffold-hopping approach, allowing to identify three new molecules that act as effective inhibitors of this protein. These molecules, synthesized and tested for their FABP4 inhibitor activity, showed IC 50 values between 3.70 and 5.59 M, with a high level of agreement with the predicted values.
Introduction
Fatty acids (FAs) are a class of carboxylic acids that carries out different vital functions in the organism [1] . Recently, it was proved that chronically elevated plasma fatty acids lead to specific physiological disorders [2] . For instance, FAs elevated levels are connected with type 2 diabetes [3] , obesity [4] and atherosclerosis [5] . Due to the poor solubility in water of FAs, their trafficking requires a cluster of specific carrier proteins, such as albumin, lipocalins and fatty acid-binding proteins (FABPs), that facilitates their transport increasing their water solubility [6] . The adipocyte FABP (A-FABP, aP2 or FABP4) is highly expressed in adipocytes and it is regulated by peroxisome-proliferator-activated receptor-c agonists, as well as by the levels of insulin and fatty acids [7] . Studies in FABP4 knockout mice have shown that FABP4 has a key role in many aspects of the metabolic syndrome [8, 9] , showing that the lack of this protein partially prevents the advancement of insulin resistance and obesity in mice.
Therefore, pharmacological agents that inhibit FABP4 function can mimic the phenotype of FABP4-deficient mice and small molecules that inhibit FABP4 might be useful candidates for the treatment of metabolic syndromes. FABPs play also an important role in carcinogenesis [10] . Modified FABPs expression were described for prostate, bladder, renal cell carcinoma and other types of cancer cells [11] [12] [13] , although FABPs biological function in cancer remains mostly unclear [14] .
Recently, a variety of effective FABP4 inhibitors have been developed [15] , but unfortunately, none of them is currently in the clinical research phases, and only BMS309403 ( Figure 1 ) has been systematically studied in both in vitro and in vivo animal models [16] [17] [18] . In Table 1 are reported the different classes of FABP4 inhibitors [15] , in Figure 1 and Table 2 some representative examples and their biological evaluations, respectively. [27, 28] . In line with our recent interest in the development of QSAR models and related applications, in order to identify novel hit compounds, herein we report the development of a 3D-QSAR approach for FABP4 [29] [30] [31] [32] [33] [34] [35] . Moreover, the 3D-QSAR model was combined with a scaffold-hopping analysis, allowing the design of new potent molecules able to interact with the binding site and inhibit the FABP4. The 3D-QSAR model for the determination of FABP4 endpoints was developed using the software Forge, while Spark was adopted to produce a scaffold-hopping analysis and generate a virtual library of FABP4 inhibitors. This 3D-QSAR model was used to elucidate SAR data and predict FABP4 endpoints for new molecules. Three of the ligands suggested by the scaffold-hopping analysis were synthesized and tested in vitro yielding IC 50 values between 3.70 and 5.59 M.
Results and discussion

Statistical analysis
The regression method used in Forge was PLS (SIMPLS algorithm) [36] [37] [38] [39] [40] . As presented in the Data in Brief related article, two different alignment methods were initially tested (i.e., structure- The statistical results of both models are reported in Table 3 and Figure 2 . As demonstrated above ( Fig. 2 , Table 3 ), the ligand-based approach results to be more reliable (r 2 = 0.92, q 2 = 0.64) than the structure-based alignment, which has an increased noise (r 2 = 0.90, q 2 = 0.38 The graphical interpretation of the model is shown in Figure 5 , where the 3D-QSAR model results are superposed to the structure of the BMS309403. In this model representation, the larger the points are and the stronger is the correlation between the electrostatic/steric fields in that position.
This 3D-QSAR model is clearly described by both steric and electrostatic effects and well describes the behavior of the different classes of FABP4 inhibitors inside the binding pocket of FABP4. To reveal the key features of the series under investigation, a structure-activity relationship (SAR) study was also performed through activity-atlas (AA) visualization software [42] . Figure 6 illustrates the results of AA calculations, where the AA map is superimposed to BMS309403 lead compound. The different colors on the map highlight electrostatic, hydrophobic and shape features.
A more positive electrostatic field increases the receptor-affinity in the red area, whereas in the blue region a more negative electrostatic field increases the affinity. Green and violet areas represent the steric and bulk/hydrophobic interactions. A steric/bulk interaction improves the binding affinity in the green area. On the other hand, in the violet area, a steric/bulk interaction decreases the affinity. 
Scaffold-hopping analysis
To design novel hit compounds with FABP4 inhibitory activity, by using the above-reported information from the QSAR model, we decided to use a bioisostere and fragment replacement software tool (i.e. Spark; Cresset group) and produce a scaffold hopping analysis to generate a virtual library of FABP4 ligands [43] . As reported in Figure 7 , Different portions of the BMS309403 were studied in the bioisosteric replacement. Once the virtual library was created, the newly designed molecules were scored assuming that if their calculated/aligned fields are highly similar to that of the original compounds present in the 3D-QSAR model, the resulting biological activity would have been comparable [44, 45] . The bioisosteric replacement was performed through the same 178,558 fragments for each part, which derive from ChEMBL and Zinc databases [46, 47] (see the Data in Brief related article). Five hundred compounds were generated for each substitution producing 3,000 hits in total, which were then scored in the 3D-QSAR model. The results of the scaffold-hopping analysis were used for the design of a novel series of BMS309403-based derivatives. In particular, we focused our attention on the results of the series 3 and 4. In series 3, the most potent compound was predicted as a thiazole derivate of the BMS309403, where the central pyrazole is substituted by a thiazole. In series 4, the most potent predicted compound was the term with a triazole as the aromatic linker, which can be easily introduced through a click chemistry reaction. Using these information, we designed the new series of compounds AST_1-3 ( Fig. 9 ). The molecules were imported into Forge and aligned/evaluated with the 3D-QSAR model. Interestingly, AST_1-3 were predicted to have a pIC 50 of 5.4, 5.9 and 5.6, respectively, and demonstrated an IC 50 of 3.98, 1.25 and 2.51 M. To prove the effective predicting capabilities of our model, we decide to set up a synthetic route that affords AST_1-3. 
Synthesis
The synthesis (Scheme 1) starts from commercially available aldehydes (i.e. benzaldehyde, naphthaldehyde, and 4-chloro benzaldehyde) and the Grignard reagent generated in situ by benzyl 
FABP4 inhibition evaluation
FABP4 inhibitory activity was determined with a commercially available screening assay kit, by measuring the decreasing in fluorescence of a detection reagent (which is supplied in the kit) when displaced by an inhibitor of FABP4. Specifically, the detection reagent exhibits increased fluorescence when bound to FABP4. Binding of the detection reagent is monitored by exciting at 370 nm and measuring the emission at 470 nm. Therefore, any powerful inhibitor of the protein, which binds to the same binding pocket, can displace the detection reagent, thereby reducing the fluorescence read-out. Inhibition activity data are expressed as IC 50 (µM) and results obtained with AST_1-3 are reported in Table 4 . Arachidonic acid, a known powerful ligand of FABP4, was used as a positive control and revealed an IC 50 of 3.06 µM. Our set of compounds, AST_1-3, showed IC 50 values of 5.59, 3.70, and 4.31, respectively. 
Conclusion
FABP4 provides an attractive therapeutic and diagnostic target for a variety of diseases as demonstrated in a variety of animal models [48] [49] [50] [51] . FABP4 inhibitors could also be effective for the treatment of cancer patients via the inhibition or reduction of early-stage tumors and metastasis.
Similarly, they show effective as biomarkers for the diagnosis of different types of cancers [52] [53] [54] [55] [56] [57] [58] .
In addition, FABP inhibitors could also be used for the treatment of neurological disorders [59] [60] [61] [62] .
In this study, a 3D-QSAR model for known FABP4 inhibitors was produced and used to study a large library of molecules as possible inhibitors of FABP4, by means of scaffold-hopping analysis.
The efficient predictive capabilities of the QSAR model was also proved through the synthesis of three new compounds as FABP4 inhibitors, using the information obtained from the QSAR 
Experimental Section
Molecular modeling and biological data
The 120 structures used to build and evaluate the 3D-QSAR model were chosen among the structures previously published [19, 21, 22, 24, 25, 63, 64] . All molecules possess an excellent selectivity toward the FABP4 and the range of activities is broad enough to be able to build an efficient model. The 2D chemical structures were built by Marvin Sketch, and all structures were subjected to molecular mechanics energy minimization using the MMFF94 force field present in the same software [65] . Once obtained the 3D structures of all compounds the geometry was also optimized at the semi-empirical level of theory using the PM3 Hamiltonian [66] , as implemented in MOPAC 2016 package [67] . 
Chemistry
All chemicals were purchased from Merk, Sigma Aldrich, and Acros Organics and were reagent grade or better. Solvents were purchased from Fisher Scientific, Sigma Aldrich, and VWR. Silica gel for column chromatography was purchased from Merck. Samples were dried in a vacuum oven (Gallenkamp, rated to ≤250 °C) connected to a vacuum pump (BOC-Edwards. 
General procedure for the synthesis of alcohols 10
A solution of benzyl bromide 8 (0.02 mol) in Et 2 O (50 mL) was dropwise added to a stirred suspension of Mg (0.025 mol) over a period of 2 h at room temperature. The mixture was stirred for 3 additional hours more at room temperature to produce benzyl Grignard 9 and cooled to -40 °C. A solution of aldehyde 7 (0.01mol) in Et 2 O (50 mL) was added over a period of 1 h. The mixture was stirred for 2 h at -40 °C, gradually brought to room temperature and stirred for 3 h more. After addition of saturated aqueous NH 4 Cl (10 mL), the mixture was extracted with EtOAc. The combined organic extracts were washed with water, brine and dried over Na 2 SO 4 . Solvent removal under reduced pressure and column chromatography of the residue (silica gel, 93/7, cyclohexane/EtOAc) afforded the pure alcohol 10. Yields 92-99%.
General procedure for the synthesis of ketones 11
A solution of 10 (8.0 mmol) was added to a stirred suspension of pyridinium chlorochromate (12 mmol) in CH 2 Cl 2 (60 mL). The mixture was stirred at room temperature for nearly 3 h until the disappearance of the starting material (monitored by TLC), diluted with diethyl ether (50 mL) and
filtered through a column of celite. Solvent removal of the filtrate under reduced pressure and column chromatography of the residue (silica gel, 95/5, cyclohexane/EtOAc) afforded pure 11.
Yields 95-99%.
General procedure for the synthesis of -bromoketone 12
Bromine (3.8 mmol) was added dropwise to a solution of 11 (2.5 mmol) in freshly distilled CHCl 3 (10 mL). The mixture was heated under reflux until conversion was complete (monitored by TLC).
After cooling, the solvent was evaporated under reduced pressure to provide a residue that was purified via column chromatography (silica gel, cyclohexane) to yield pure -bromoketone 12.
Yields 70-85%.
General procedure for the synthesis of 2-Aminothiobenzamide 14
Lawesson's reagent (8.0 mmol) was added to a solution of 13 (14.7 mmol) in THF (75 mL). The mixture was stirred under N 2 at room temperature for 24h. The solvent was evaporated, and the residue partitioned between EtOAc (50 mL), and 1 N HCl (30 mL). Aqueous sat. NaHCO 3 was added to the aqueous layer until pH= 8-9. This basic solution was extracted with EtOAc (30 mL).
The combined organic layers were dried (Na 2 SO 4 ) and filtered. The solvent was evaporated and the resulting solid residue was recrystallized from toluene to afford pure 14 as a yellow solid; yield 72%.
General procedure for the synthesis of thiazole 15
The 2-aminothiobenzamide 14 (1.5 mmol) was added to a solution of -bromoketone 12 ( 
FABP inhibitory activity assays
To analyze the inhibitory activity of FABP4 ligands, a displacement assay was utilized as described 
Appendix A. Supplementary data
Supplementary data related to this article can be found at https://doi.org/
